Icosavax, Inc. (ICVX)

NASDAQ: ICVX · IEX Real-Time Price · USD
16.51 0.27 (1.66%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap644.58M
Revenue (ttm)1.62M
Net Income (ttm)-53.40M
Shares Out39.04M
EPS (ttm)-6.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,782
Open15.87
Previous Close16.24
Day's Range15.58 - 16.61
52-Week Range15.58 - 49.99
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ICVX

Icosavax is a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our pipeline includes vaccine candidates targeting some of the most prevalent viral causes of pneumonia. We are developing these candidates for older adults, a patient population with high unmet need. Our vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates, designed to target resp...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOAdam Simpson
Employees28
Stock ExchangeNASDAQ
Ticker SymbolICVX
Full Company Profile

Financial Performance

Financial Statements

News

Icosavax Provides Corporate Update and Anticipated Milestones for 2022

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

1 week ago - GlobeNewsWire

Icosavax Appoints Dr. John Shiver to Board of Directors

- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases - - Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious...

1 week ago - GlobeNewsWire

Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

2 months ago - GlobeNewsWire

Icosavax to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

2 months ago - GlobeNewsWire

Icosavax co-founder and UW researcher Neil King talks vaccine development in the ‘digital era'

We are now in the “digital era” of vaccine development, University of Washington researcher Neil King said at the GeekWire Summit in Seattle on Tuesday.

3 months ago - GeekWire

Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain -

4 months ago - GlobeNewsWire

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

4 months ago - GlobeNewsWire

Adams Street Partners Growth Equity Strategy Participates in Three High-Profile Public Offerings In Seven Days

MENLO PARK, Calif.--(BUSINESS WIRE)--Adams Street Partners, a private markets investment firm with $45 billion in assets under management, announced today that within a 7-day period last week three comp...

Other symbols:BASEHOOD
5 months ago - Business Wire

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additiona...

SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

5 months ago - GlobeNewsWire

Icosavax stock skyrockets 200% on first day of trading for newly public Seattle biotech company

Icosavax is having quite the debut as Washington state's newest public company.

5 months ago - GeekWire

Icosavax Announces Pricing of Upsized Initial Public Offering

SEATTLE--(BUSINESS WIRE)--Icosavax Announces Pricing of Upsized Initial Public Offering

5 months ago - Business Wire